Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
Accepted date: 26 Sep 2021
Published date: 15 Sep 2022
Copyright
Yao Zhao , Chao Fang , Qi Zhang , Ruxue Zhang , Xiangbo Zhao , Yinkai Duan , Haofeng Wang , Yan Zhu , Lu Feng , Jinyi Zhao , Maolin Shao , Xiuna Yang , Leike Zhang , Chao Peng , Kailin Yang , Dawei Ma , Zihe Rao , Haitao Yang . Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332[J]. Protein & Cell, 2022 , 13(9) : 689 -693 . DOI: 10.1007/s13238-021-00883-2
1 |
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H et al (2021) Discovery of a novel inhibitor of coronavirus 3CL protease for the potential treatment of COVID-19. BbioRxiv 1: 2020- 2029
|
2 |
Cui W, Yang K, Yang H (2020) Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19. Front Mol Biosci 7: 616341
|
3 |
Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F et al (2020) Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368: 1331- 1335
|
4 |
Fu L, Ye F, Feng Y, Yu F, Wang Q, Wu Y, Zhao C, Sun H, Huang B, Niu P et al (2020) Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11: 4417
|
5 |
Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, He M, Hogan RJ, Kozminski K, Li LY et al (2020) Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J Med Chem 63: 12725- 12747
|
6 |
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C et al (2020) Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582: 289- 293
|
7 |
Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, Abeles SR, Torriani FJ (2021) Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. N Engl J Med 384: 1774- 1775
|
8 |
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395: 565- 574
|
9 |
Manns MP, von Hahn T (2013) Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 12: 595- 610
|
10 |
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF (2021) Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol 21: 626- 636
|
11 |
Vandyck K, Deval J (2021) Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol 49: 36- 40
|
12 |
Wang F, Chen C, Tan W, Yang K, Yang H (2016) Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design. Sci Rep 6: 22677
|
13 |
Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Zhao Q, Zhou Z, Pei D, Ziebuhr J et al (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 3: e324
|
14 |
Zhao Y, Du X, Duan Y, Pan X, Sun Y, You T, Han L, Jin Z, Shang W, Yu J et al (2021) High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell
|
15 |
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054- 1062
|
/
〈 | 〉 |